Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.

Li QF, Yao RY, Liu KW, Lv HY, Jiang T, Liang J.

J Korean Med Sci. 2010 Jun;25(6):846-52. doi: 10.3346/jkms.2010.25.6.846. Epub 2010 May 24.

2.

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.

Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ.

J Natl Cancer Inst. 2002 Jun 19;94(12):936-42.

PMID:
12072547
3.

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.

Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ.

Eur J Cancer. 2009 Mar;45(4):572-8. doi: 10.1016/j.ejca.2008.10.015. Epub 2008 Dec 10.

PMID:
19084393
4.

Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients.

Ott K, Lordick F, Becker K, Ulm K, Siewert J, Höfler H, Keller G.

Int J Colorectal Dis. 2008 Aug;23(8):773-82. doi: 10.1007/s00384-008-0490-4. Epub 2008 Apr 29.

PMID:
18443805
5.

Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.

Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD.

Mol Med Rep. 2013 Jun;7(6):1904-11. doi: 10.3892/mmr.2013.1435. Epub 2013 Apr 22.

PMID:
23604281
6.

Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

Huang ZH, Hua D, Du X.

Cancer Chemother Pharmacol. 2009 Oct;64(5):1001-7. doi: 10.1007/s00280-009-0956-2. Epub 2009 Feb 27.

PMID:
19247656
7.

[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].

Liang J, Li QF, Yao RY, Lü HY, Jiang J, Sun YY, Song SA, Jiang T.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):515-9. Chinese.

PMID:
21029695
8.

[Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].

Liu YP, Ling Y, Zhang YP, Liu BR.

Zhonghua Yi Xue Za Zhi. 2011 Jan 25;91(4):256-9. Chinese.

PMID:
21418871
9.

Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.

Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L.

Eur J Hum Genet. 2007 Oct;15(10):1049-53. Epub 2007 Jun 27.

10.
11.

Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.

Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS.

Cancer Sci. 2010 Feb;101(2):530-5. doi: 10.1111/j.1349-7006.2009.01418.x. Epub 2009 Oct 28.

12.

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.

Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J.

Br J Cancer. 2006 Jan 30;94(2):281-6.

13.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A.

Br J Clin Pharmacol. 2010 Jan;69(1):58-66. doi: 10.1111/j.1365-2125.2009.03556.x.

14.
15.
16.

A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.

Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ.

Chemotherapy. 2008;54(3):228-35. doi: 10.1159/000140467. Epub 2008 Jun 18.

PMID:
18560231
17.

Ile105Val GSTP1 polymorphism and susceptibility to colorectal carcinoma in Bulgarian population.

Vlaykova T, Miteva L, Gulubova M, Stanilova S.

Int J Colorectal Dis. 2007 Oct;22(10):1209-15. Epub 2007 Apr 3.

PMID:
17404745
18.

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.

Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJ, Guchelaar HJ.

Br J Cancer. 2008 Oct 21;99(8):1316-21. doi: 10.1038/sj.bjc.6604654. Epub 2008 Sep 16.

19.

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J.

J Clin Oncol. 2009 Jun 10;27(17):2863-73. doi: 10.1200/JCO.2008.19.1718. Epub 2009 Mar 30.

PMID:
19332728
20.

Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.

Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, Robert J.

Pharmacogenomics. 2007 Dec;8(12):1693-703.

PMID:
18085999

Supplemental Content

Support Center